IBIO•benzinga•April 7, 2025 at 11:07 AM

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And

No summary available.

Read the full article from the original source for complete details and context.

Article published on April 7, 2025 by benzinga